Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05833971Phase 2Not yet recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Pathologic Complete Response. Planned start May 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05833971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833971.